Effect of #Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With #COVID-19 Pneumonia
The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.. ..Patients in the experimental arm received intravenous tocilizumab within 8 hours from randomization (8 mg/kg up to a maximum of 800 mg), followed by a second dose after 12 hours. Patients in the control arm … Continue reading Effect of #Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With #COVID-19 Pneumonia